Medicines are becoming a luxury many can’t afford—and it’s hitting patients hard. Imagine needing eye drops for inflammation, only to find their price has skyrocketed by 233% in just a few months. This isn’t a hypothetical scenario; it’s the stark reality for patients in Malta, where a broad range of medicines have seen staggering price increases. Flarex eye drops, for instance, jumped from €5.31 to €17.10, while Otosporin ear drops surged from €4.61 to €13.95—a 200% hike. But it doesn’t stop there. Everyday essentials like Buscopan tablets, Sudocrem, and Ventolin inhalers are also digging deeper into consumers’ pockets. A 250g tub of Sudocrem, a staple for treating baby skin redness, shot up by 72%, and Buscopan now costs double what it used to. Asthma sufferers are feeling the pinch too, with Ventolin inhalers rising by 137%.
But here’s where it gets controversial: These price hikes aren’t just about inflation. While the National Statistics Office reports a moderate 2.9% annual inflation rate for medical services, the reality on the ground is far more brutal. A pharmacist, who compiled a list of around 100 medicines over 18 months, revealed increases ranging from 2% to over 200%. Pain relievers, fertility medications—nothing seems spared. Even medicines that saw price reductions in 2023, like Septrin Forte and Anthisan, have rebounded to higher costs. So, what’s driving these spikes? Some point to Malta’s small market size and post-Brexit import challenges, while others blame higher registration fees introduced by the Medicines Authority. And this is the part most people miss: Patients often have no choice but to pay these prices, especially when prescribed specific branded medications with no alternatives.
Here’s the kicker: Despite Malta’s Pharmacy of Your Choice (POYC) scheme offering free medicines, Maltese families still spend the second-highest amount on pharmaceuticals in the EU. According to the OECD, retail medicines accounted for 18% of Malta’s total health expenditure in 2023, compared to the EU average of 13%. On a per capita basis, that’s €648 per person—a staggering financial burden. While the government claims it’s negotiating price reductions for 33 medicines, the question remains: Is it enough?
Now, let’s stir the pot: Are these price hikes a result of market forces beyond Malta’s control, or is there more to the story? Could incentives from importers to doctors and pharmacies be inflating costs artificially? And what role does Malta’s unique position post-Brexit play in all this? Weigh in below—do you think the government is doing enough to protect patients from these soaring costs? Or is this a systemic issue that requires a complete overhaul of how medicines are priced and distributed?
